PMID- 23022159
OWN - NLM
STAT- MEDLINE
DCOM- 20130221
LR  - 20211021
IS  - 1879-1891 (Electronic)
IS  - 0002-9394 (Linking)
VI  - 155
IP  - 1
DP  - 2013 Jan
TI  - Subretinal fluid in uveitic macular edema: effect on vision and response to 
      therapy.
PG  - 143-9
LID - S0002-9394(12)00483-7 [pii]
LID - 10.1016/j.ajo.2012.06.028 [doi]
AB  - PURPOSE: To evaluate the effect of subretinal fluid (SRF), imaged with 
      spectral-domain optical coherence tomography (SD-OCT), on visual acuity outcomes 
      in cases of uveitic macular edema (ME), and to analyze the response of SRF and 
      uveitic ME to therapy. DESIGN: Retrospective case series. METHODS: One hundred 
      and one eyes of 75 patients with uveitic ME, as imaged by SD-OCT, were identified 
      at a single tertiary-care referral center. The main outcome measures were 
      best-corrected visual acuity, central subfield thickness (CSFT), and rates of 
      macular edema improvement (>/=20% reduction in CSFT), and resolution (defined as 
      reduction of CSFT to <315 mum) of ME at 3 and 6 months follow-up. RESULTS: Forty 
      eyes of 29 patients had SRF on SD-OCT at presentation, which was associated with 
      greater macular thickness (mean CSFT 488 mum vs 362 mum, P = .0001) and worse 
      visual acuity than ME without SRF (20/115 vs 20/51, P = .015). However, eyes with 
      SRF responded more favorably to treatment, and at 3 and 6 months of follow-up 
      they achieved greater rates of improvement and resolution of ME than eyes without 
      SRF (77% improved and 50% resolved at 6 months, vs 20% and 13%, respectively; P = 
      .003 and P = .017, respectively) and recovered to a similar level of visual 
      acuity (20/62 vs 20/42 at 6 months, P = .54). CONCLUSIONS: SRF in uveitic ME is 
      associated with thicker retinas and worse visual acuity on presentation but 
      responds more favorably to treatment and displays greater rates of edema 
      resolution and visual acuity improvement.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Lehpamer, Brian
AU  - Lehpamer B
AD  - Department of Ophthalmology, The Mount Sinai School of Medicine, New York, New 
      York, USA.
FAU - Moshier, Erin
AU  - Moshier E
FAU - Goldberg, Naomi
AU  - Goldberg N
FAU - Ackert, Jessica
AU  - Ackert J
FAU - Godbold, James
AU  - Godbold J
FAU - Jabs, Douglas A
AU  - Jabs DA
LA  - eng
GR  - UL1 RR029887/RR/NCRR NIH HHS/United States
PT  - Journal Article
DEP - 20120927
PL  - United States
TA  - Am J Ophthalmol
JT  - American journal of ophthalmology
JID - 0370500
RN  - 0 (Glucocorticoids)
RN  - 0 (Immunosuppressive Agents)
SB  - IM
MH  - Exudates and Transudates
MH  - Female
MH  - Follow-Up Studies
MH  - Glucocorticoids/therapeutic use
MH  - Humans
MH  - Immunosuppressive Agents/therapeutic use
MH  - Macular Edema/drug therapy/*physiopathology
MH  - Male
MH  - Retina/*pathology
MH  - Retrospective Studies
MH  - Subretinal Fluid/*physiology
MH  - Tomography, Optical Coherence
MH  - Uveitis/drug therapy/*physiopathology
MH  - Vision Disorders/physiopathology
MH  - Visual Acuity/*physiology
EDAT- 2012/10/02 06:00
MHDA- 2013/02/22 06:00
CRDT- 2012/10/02 06:00
PHST- 2012/02/13 00:00 [received]
PHST- 2012/06/20 00:00 [revised]
PHST- 2012/06/27 00:00 [accepted]
PHST- 2012/10/02 06:00 [entrez]
PHST- 2012/10/02 06:00 [pubmed]
PHST- 2013/02/22 06:00 [medline]
AID - S0002-9394(12)00483-7 [pii]
AID - 10.1016/j.ajo.2012.06.028 [doi]
PST - ppublish
SO  - Am J Ophthalmol. 2013 Jan;155(1):143-9. doi: 10.1016/j.ajo.2012.06.028. Epub 2012 
      Sep 27.